We are live on ! Find out more
ENGN icon

enGene Therapeutics
ENGN

31 hedge funds and large institutions have $536M invested in enGene Therapeutics in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 2

309% more capital invested

Capital invested by funds: $131M → $536M (+$405M)

182% more funds holding

Funds holding: 11 → 31 (+20)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

11.49% more ownership

Funds ownership: 61.15% → 72.64% (+11%)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
31
Holders Change
+20
Holders Change %
+181.82%
% of All Funds
0.45%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
22
Increased
2
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
+$31.4M
2
DTC
Deep Track Capital
Connecticut
+$27.5M
3
CC
Commodore Capital
New York
+$15.3M
4
BOCH
Blue Owl Capital Holdings
New York
+$15M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$14.7M

Top Sellers

Rank Fund Capital Flow
1
OFM
Omega Fund Management
Massachusetts
-$671K
2
PAMP
Polar Asset Management Partners
Ontario, Canada
-$633K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$366K
4
Goldman Sachs
Goldman Sachs
New York
-$346K
5
UBS Group
UBS Group
Switzerland
-$17.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
FIS
1
FCPM III Services
Netherlands
$147M – – –
VA
2
VR Adviser
New York
$43.5M +$31.4M +2,565,841 New
BOCH
3
Blue Owl Capital Holdings
New York
$41.7M +$15M +1,226,590 +99%
BI
4
BVF Inc
California
$38.2M – – –
DTC
5
Deep Track Capital
Connecticut
$38.1M +$27.5M +2,250,000 New
CC
6
Commodore Capital
New York
$21.2M +$15.3M +1,250,000 New
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$20.3M +$14.7M +1,200,000 New
OFM
8
Omega Fund Management
Massachusetts
$18.2M -$671K -54,818 -5%
Janus Henderson Group
9
Janus Henderson Group
United Kingdom
$17.1M +$12.2M +1,000,000 New
CAM
10
Cormorant Asset Management
Massachusetts
$16.9M +$12.2M +1,000,000 New
PA
11
Perceptive Advisors
New York
$16.9M +$12.2M +998,888 New
Citadel Advisors
12
Citadel Advisors
Florida
$13.6M +$9.59M +784,121 +3,909%
DM
13
Deerfield Management
New York
$13.6M +$9.79M +800,000 New
Franklin Resources
14
Franklin Resources
California
$13.6M +$9.79M +800,000 New
Marshall Wace
15
Marshall Wace
United Kingdom
$13.6M +$9.79M +800,000 New
SCM
16
Soleus Capital Management
Connecticut
$13.6M +$9.79M +800,000 New
LGM
17
Logos Global Management
California
$12.9M +$9.79M +800,000 New
BC
18
Boxer Capital
California
$12.3M +$8.91M +727,900 New
VC
19
Vivo Capital
California
$11.5M – – –
GTC
20
Ghost Tree Capital
New York
$3.39M +$2.45M +200,000 New
Point72 Asset Management
21
Point72 Asset Management
Connecticut
$3.09M +$2.23M +182,586 New
ACP
22
Altitude Crest Partners
Connecticut
$2.04M +$1.47M +120,289 New
PAMP
23
Polar Asset Management Partners
Ontario, Canada
$1.1M -$633K -51,717 -44%
Verition Fund Management
24
Verition Fund Management
Connecticut
$1.06M +$764K +62,422 New
SSA
25
Schonfeld Strategic Advisors
New York
$859K +$620K +50,700 New
1
2

ENGN Hedge Fund Activity: Q1 2024 in Review

31 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q1 2024, worth a combined $536M — up 309% from $131M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ENGN positions and 2 closed out — a net gain of 20 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was VR Adviser, opening a new position worth an estimated $31.4M. The largest seller was Omega Fund Management, cutting an estimated $671K.

  • 31 institutional investors held enGene Therapeutics (ENGN) as of Q1 2024, up from 11 in Q4 2023.
  • Funds reported $536M of enGene Therapeutics stock for Q1 2024, up 309% quarter-over-quarter.
  • 22 funds opened new enGene Therapeutics positions in Q1 2024 and 2 closed out, a net change of +20 holders.
  • The largest enGene Therapeutics buyer in Q1 2024 was VR Adviser, an estimated $31.4M added.
  • The largest enGene Therapeutics seller in Q1 2024 was Omega Fund Management, an estimated $671K sold.

Based on aggregated 13F filings for Q1 2024.